Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFS NYSE:GKOS NASDAQ:SLNO NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$28.79+0.5%$26.11$19.10▼$29.62$1.37B1.95371,197 shs267,911 shsGKOSGlaukos$74.60-0.9%$86.40$73.73▼$163.71$4.32B0.761.04 million shs1.31 million shsSLNOSoleno Therapeutics$64.18+0.8%$63.74$41.50▼$90.32$3.38B-2.751.46 million shs603,158 shsTMDXTransMedics Group$130.52+1.2%$115.94$55.00▼$145.50$4.45B2.08851,499 shs891,884 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions+0.45%+5.38%+19.41%+27.50%+31.22%GKOSGlaukos-0.91%-14.73%-9.91%-20.87%-42.58%SLNOSoleno Therapeutics+0.82%-1.97%-0.50%-25.78%+21.78%TMDXTransMedics Group+1.25%+10.96%+11.15%+20.72%+9.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$28.79+0.5%$26.11$19.10▼$29.62$1.37B1.95371,197 shs267,911 shsGKOSGlaukos$74.60-0.9%$86.40$73.73▼$163.71$4.32B0.761.04 million shs1.31 million shsSLNOSoleno Therapeutics$64.18+0.8%$63.74$41.50▼$90.32$3.38B-2.751.46 million shs603,158 shsTMDXTransMedics Group$130.52+1.2%$115.94$55.00▼$145.50$4.45B2.08851,499 shs891,884 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions+0.45%+5.38%+19.41%+27.50%+31.22%GKOSGlaukos-0.91%-14.73%-9.91%-20.87%-42.58%SLNOSoleno Therapeutics+0.82%-1.97%-0.50%-25.78%+21.78%TMDXTransMedics Group+1.25%+10.96%+11.15%+20.72%+9.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 2.67Moderate Buy$31.298.67% UpsideGKOSGlaukos 2.69Moderate Buy$116.9256.73% UpsideSLNOSoleno Therapeutics 2.93Moderate Buy$115.9280.61% UpsideTMDXTransMedics Group 2.62Moderate Buy$130.730.16% UpsideCurrent Analyst Ratings BreakdownLatest BLFS, GKOS, TMDX, and SLNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025GKOSGlaukosWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/25/2025SLNOSoleno TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025BLFSBioLife SolutionsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025TMDXTransMedics GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/23/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$148.0010/20/2025GKOSGlaukosBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$104.0010/14/2025TMDXTransMedics GroupCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$142.0010/13/2025GKOSGlaukosBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$118.00 ➝ $104.0010/13/2025TMDXTransMedics GroupJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$145.0010/8/2025BLFSBioLife SolutionsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GKOSGlaukosWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$82.25M16.77$0.12 per share233.94$7.52 per share3.83GKOSGlaukos$383.48M11.16N/AN/A$13.91 per share5.36SLNOSoleno Therapeutics$32.66M104.44N/AN/A$5.68 per share11.30TMDXTransMedics Group$531.29M8.37$1.67 per share78.35$6.81 per share19.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$20.18M-$0.12N/AN/AN/A-5.39%0.16%0.14%11/6/2025 (Estimated)GKOSGlaukos-$146.37M-$1.65N/AN/AN/A-21.43%-8.59%-6.61%10/29/2025 (Confirmed)SLNOSoleno Therapeutics-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%11/4/2025 (Estimated)TMDXTransMedics Group$35.46M$1.9367.6391.27N/A13.49%28.02%8.64%10/29/2025 (Estimated)Latest BLFS, GKOS, TMDX, and SLNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025BLFSBioLife Solutions-$0.01N/AN/AN/A$25.69 millionN/A11/5/2025Q3 2025SLNOSoleno Therapeutics$0.08N/AN/AN/A$47.46 millionN/A10/29/2025Q3 2025GKOSGlaukos-$0.27N/AN/AN/A$122.55 millionN/A10/29/2025Q3 2025TMDXTransMedics Group$0.37N/AN/AN/A$145.33 millionN/A8/7/2025Q2 2025BLFSBioLife Solutions-$0.02-$0.33-$0.31-$0.33$23.71 million$25.42 million8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 million7/30/2025Q2 2025GKOSGlaukos-$0.26-$0.24+$0.02-$0.34$115.49 million$124.12 million7/30/2025Q2 2025TMDXTransMedics Group$0.48$0.92+$0.44$0.92$146.64 million$157.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/AGKOSGlaukosN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife SolutionsN/A4.433.45GKOSGlaukos0.095.514.69SLNOSoleno Therapeutics0.2115.1315.01TMDXTransMedics Group1.619.869.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%GKOSGlaukos99.04%SLNOSoleno Therapeutics97.42%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%GKOSGlaukos5.80%SLNOSoleno Therapeutics6.40%TMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.90 million46.85 millionOptionableGKOSGlaukos78057.35 million54.02 millionOptionableSLNOSoleno Therapeutics3053.15 million49.74 millionOptionableTMDXTransMedics Group21034.09 million31.70 millionOptionableBLFS, GKOS, TMDX, and SLNO HeadlinesRecent News About These Companies2,135 Shares in TransMedics Group, Inc. $TMDX Purchased by Vanguard Personalized Indexing Management LLCOctober 25 at 3:18 AM | marketbeat.comNeedham Upgrades TransMedics Group (TMDX)October 24 at 7:46 PM | msn.comNeedham Upgrades TransMedics Group (TMDX)October 24 at 7:46 PM | msn.comOppenheimer Reaffirms Their Buy Rating on TransMedics Group (TMDX)October 24 at 7:46 PM | theglobeandmail.comTransMedics Group (NASDAQ:TMDX) Upgraded to "Buy" at Needham & Company LLCOctober 23 at 7:40 AM | marketbeat.comTransMedics (TMDX) Reports Next Week: Wall Street Expects Earnings GrowthOctober 22 at 11:06 AM | zacks.com2,442 Shares in TransMedics Group, Inc. $TMDX Purchased by Atria Wealth Solutions Inc.October 22 at 3:36 AM | marketbeat.com4,171 Shares in TransMedics Group, Inc. $TMDX Purchased by Envestnet Portfolio Solutions Inc.October 22 at 3:36 AM | marketbeat.comTransMedics Group (TMDX) to Release Earnings on WednesdayOctober 22 at 3:01 AM | americanbankingnews.comTransMedics Group (TMDX) to Release Quarterly Earnings on WednesdayOctober 22 at 3:00 AM | marketbeat.comNew York State Teachers Retirement System Buys 5,689 Shares of TransMedics Group, Inc. $TMDXOctober 21, 2025 | marketbeat.comTransMedics Group: Guidance Up, Durability In QuestionOctober 20, 2025 | seekingalpha.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by AnalystsOctober 20, 2025 | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 20, 2025 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Rating Increased to Buy at Wall Street ZenOctober 18, 2025 | marketbeat.comTransMedics Group, Inc. $TMDX Shares Sold by Vontobel Holding Ltd.October 16, 2025 | marketbeat.comTransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025October 15, 2025 | prnewswire.comTransMedics Group (NASDAQ:TMDX) Coverage Initiated at Jefferies Financial GroupOctober 15, 2025 | americanbankingnews.comTransMedics Group Advances Healthcare Amid Nasdaq 100 Index RiseOctober 14, 2025 | kalkinemedia.comKTransMedics Group Stock Earns Relative Strength Rating UpgradeOctober 14, 2025 | msn.comTransMedics Group (NASDAQ:TMDX) Earns "Buy" Rating from Canaccord Genuity GroupOctober 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLFS, GKOS, TMDX, and SLNO Company DescriptionsBioLife Solutions NASDAQ:BLFS$28.79 +0.13 (+0.45%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$28.78 -0.01 (-0.03%) As of 10/24/2025 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.Glaukos NYSE:GKOS$74.60 -0.66 (-0.87%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$75.08 +0.47 (+0.63%) As of 10/24/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Soleno Therapeutics NASDAQ:SLNO$64.18 +0.52 (+0.82%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$64.36 +0.17 (+0.27%) As of 10/24/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.TransMedics Group NASDAQ:TMDX$130.52 +1.61 (+1.25%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$131.50 +0.98 (+0.75%) As of 10/24/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
